Xenogenized vaccine cells persist in vivo, preventing tumor attack.

2003 JUN 18 - (NewsRx.com & NewsRx.net) -- Investigators have released evidence that xenogenized vaccine cells persist in vivo, inducing tumor immunity.

"Trioma cell vaccination is a potent new immunotherapeutic strategy for the treatment of B cell neoplasias. It is based on the specific redirection of tumor antigens against surface receptors on professional antigen-presenting cells (APC) that internalize antigens and present immunogenic peptides to T-lymphocytes. Tumor cells are converted to trioma cells by fusion with xenogeneic hybridomas expressing an anti-APC specificity," researchers in Germany report.

"The trioma cell is a polyvalent vaccine that contains potentially all lymphoma-derived antigens," stated Nicolas Graf and collaborators at GSF-Institut fur Molekulare Immunologie in Munich. "Apart from the expression of the APC-binding arm by the trioma cell, another requirement for successful tumor protection is the xenogeneic moiety of the trioma cells. We show that, despite their xenogenicity, trioma cells persist for extended periods in vaccinated animals.

"Trioma cells could be identified in spleens as long as about 12 weeks post ...